At first the specificity test recommended for con-
The third phase tests for hepatitis B surface antigen (HBsAg)-passive haemagglutination (pHA) and radioimmunoassay (RIA)-are now well established. Although regarded as the most sensitive and most specific, the RIA test has its disadvantages; it is expensive, the reagents have a short shelf-life, and it requires specialised equipment and radiological protection.
Enzyme-linked immunosorbent assays were devised by Engvall and Perlmann (1971) and their wide application has been indicated by Voller et al. (1976) . An assay of this type was developed by Wolters et al. (1976) for HBsAg detection. The Virus Reference Laboratory was able to assess its performance as part of an organised multicentred study (Kacaki et al., 1977b) before the reagents were available commercially.
Material and methods

TECHNIQUES
A commercial ELISA test system (Hepanostika) developed by Organon Scientific Development Group was used as described by Wolters et al. (1976 Electrophoresis (IEOP) was performed as previously described (Pesendorfer et al., 1970 Four hundred and ninety-seven received for routine testing were also screened. These were selected from consecutive specimens submitted to the laboratory, the only criterion for selection being that there was sufficient material for confirmation of aberrant results.
All but seven specimens were sera. Of the remainder, six were commercial factor VIII concen-714
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Results
The sensitivity of the ELISA system when used to titrate sera of ad and ay subtypes was greater than the Ausria II system (Table 2) . However, the titres detected were so high that in routine practice this difference is probably not significant. Of the total of 773 specimens tested, 38 were positive by both Hepanosticon and ELISA (Table 1) (25 of these were also positive by electrophoresis). A further 39 were negative by Hepanosticon but positive by ELISA; 28 of these were convalescent specimens from proven cases of hepatitis B taken 3 to 13 weeks after onset. Of these, all but one (taken one month after the onset of acute hepatitis B) were positive by Ausria II and/or Hepatest. Another three specimens from patients recovering from acute hepatitis B which were negative by both Hepanosticon and ELISA were weakly positive by RIA. The two specimens positive by Hepanosticon but negative by ELISA were also negative by Hepatest and RIA. However, they were both heterophil antibody positive (Paul-Bunnell test) and were from clinical cases of infectious mononucleosis with mild jaundice.
The urine from the seropositive patient with glomerulonephritis was positive by both ELISA and RIA but negative by Hepanosticon.
The factor VIII concentrates were all negative by ELISA (although one which was positive on the initial screening test was negative when repeated and tested for specificity). In the Ausria II test all had ratios above 1 but only one was above 2-1-the level regarded as significant when serum is tested. 
Discussion
